Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤MRD revenue $72.6 million, up 28% year over year
- ➤Adjusted EBITDA $14.3 million; free cash flow reached $7.7 million
- ➤MRD revenue guidance raised to $276 million-$286 million for 2026
- ➤clonoSEQ tests reached 39,587, increasing 46% year over year
- ➤Total revenue $83.9 million, down 11% year over year
Expert Statements
Chad Robins, Chief executive officer and co-founder of Adaptive Biotechnologies
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue”
Chad Robins, Chief executive officer and co-founder of Adaptive Biotechnologies
“This momentum supports another increase in our full year outlook.”
Chad Robins, Chief executive officer and co-founder of Adaptive Biotechnologies
“Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026.
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”
Get started
Create a free account to read the full story.